Hyderabad, September 21, 2016: Dr. Reddy’s Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has launched Paricalcitol Injection, USP, in 2 mcg, 5 mcg, 10 mcg, a therapeutic equivalent generic version of Zemplar®(paricalcitol) Injection in the United States market approved by the U.S. Food & Drug Administration (USFDA).
The Zemplar® brand and generic had U.S. sales of approximately $22.5 million MAT for the most recent twelve months ending in July 2016 according to IMS Health*.
Dr. Reddy’s Paricalcitol Injection is available in 2 mcg, 5 mcg, and 10 mcg, and is the first ANDA product launched in the US market.
Zemplar® is a registered trademark of ABBVIE Inc.
*IMS National Sales Perspective: Retail and Non-Retail MAT July 2016
RDY-0916-132
Corporate Comm India (CCI Newswire)
Initiative aimed at enhancing workforce skills and competency in line with industry standards so as…
Previously, the patient underwent an above-knee amputation in the USA due to similar complications in the…
New Delhi, December 27, 2024: A team of expert obstetricians & neonatologists at Motherhood Hospitals,…
By Dr. Khushali Lalcheta, Consultant Physician, HCG Hospitals, Rajkot Diabetes is often a misunderstood condition that…
By Dr. Balaji B S, Consultant - Neurology & Epileptology, Aster Whitefield Hospital, Bengaluru Foreign…
New Delhi, December 27, 2024: Aakash Healthcare Super Specialty Hospital, New Delhi, has taken a…